News and Trends 15 Dec 2016 10 Awesome Biotech Gifts for you and your Geekiest Loved Ones Stuck on what to get your family and friends for Christmas? What about portable lab equipment or a stuffed version of your favorite microorganism? Biotech is one of the fastest growing sectors worldwide and a big employer in Europe. Providing solutions to cure, feed and fuel the world, who wouldn’t want to brag about this amazing field? Whether […] December 15, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2016 Swedish Therapy targeting All Solid Tumors enrolls First Patient Immunicum just received FDA approval to start clinical trials in the US for a therapy that could overcome the challenges of T-cell therapies and target virtually any injectable solid tumor. Immunicum is a biotech from Gothenburg, Sweden, that focuses on immuno-oncology with a different approach from most companies. Instead of T-cells, the company engineers dendritic […] December 14, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2016 How Will Biotech Overcome the Huge Challenges of Microbial Resistance? The emergence of multi-drug resistant pathogens is alarming the scientific community since their growth is increasing at an incredibly fast pace. We gathered a group of experts to discuss how biotech is addressing this pressing concern and what the next big thing will be in the field of antimicrobial resistance. Achim Plum, CCO of Curetis, highlighted that […] December 13, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Paris takes the lead in Digital Health for Diabetes Type 2 The smell of freshly baked baguettes and good news from the capital have brought us this week to France. Voluntis has received market approval for a device that could change the life of millions of people with diabetes type 2, check out this cool company! City: Paris, France Founded: 2001 Employees: 100 Financial data: Total of €29.8M raised in […] December 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Galapagos gets another Milestone Payment from Gilead Galapagos is starting a new PhaseIIb/III clinical trial for ulcerative colitis that has triggered a €9.4M milestone payment from Gilead. Can this partnership beat out its many competitors? Galapagos is one of the few billion-euro biotechs in Europe, boasting top-level partnerships with AbbVie for cystic fibrosis and MorphoSys for inflammatory diseases. The company now has news […] December 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Our Startup Battle Winner uses CRISPR in a Whole New Way Eligo Bioscience came out on top in the Startup Battle at Labiotech Refresh, watch the founder’s pitch to see how! CRISPR can be used to cut and replace virtually any gene, which has fueled a fierce patent battle over the rights to use it for gene therapy in humans. Eligo Bioscience, however, focuses on using this powerful tool to […] December 9, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 Meet the Newest ALS Pioneer Company from Switzerland AL-S Pharma was just born with the only purpose of developing a drug candidate for ALS, a rare condition for which no effective treatments exist. The parents of the newborn company are Neurimmune, a biotech from Zurich that uses high throughput technology to develop treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s, and TVM Capital Life Science. […] December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 The Munich Biotech Mafia expand to the US with a New TCR Startup TCR2 Therapeutics was backed by the Munich biotech mafia, a group of wealthy veteran biotech leaders that seem to be taking over the promising immuno-oncology field. TCR2 Therapeutics has kicked off with a €41.2M ($44.5M) Series A round led by MPM Capital in the US and F2 Ventures in London. The new company, based in Boston, […] December 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 UPDATE: No Clear Winner in the CRISPR Patent Battle Today marks an inflection point in the future of medicine: both parties fighting for the ownership of CRISPR have made their oral arguments in front of a jury. Who will win the rights to exploit a technology that could be used to cure any genetic disease? CRISPR has been hailed as the ‘scientific discovery of the […] December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 Video: How is European Biotech changing the World? We had the amazing opportunity to hear an overview of biotech in Europe at Labiotech Refresh from Philippe Pouletty, co-founder and managing director of Truffle Capital. Philippe has an incredibly extensive experience in biotech as a founder of multiple companies and VCs. He witnessed how biotech got big over the years with the first innovations coming […] December 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2016 Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies Nordic Nanovector has bagged €55M to push its pipeline forward through the clinic. Investors seem to be attracted by its ARC and ADC programs, using some of the hottest antibody technologies to treat cancer. Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat non-Hodgkin lymphoma (NHL) and recently entered the trending antibody-drug conjugate (ADC) field to fight against leukemia. These […] December 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2016 UPDATE: More Good News on a Cannabis Derivative for Epilepsy Update (07/12/2017): GW Pharma has announced more positive Phase III results for Epidiolex, pushing the drug closer to the market and a win for supporters of legalizing marijuana. Originally published on 27/09/2016 GW Pharmaceuticals just released the results of its third successful Phase III clinical trial for Epidiolex (cannabidiol), a drug that can reduce the frequency of […] December 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email